Medindia LOGIN REGISTER
Medindia
Advertisement

Reportlinker Adds The Worldwide Market for Cancer Diagnostics, 4th Edition

Tuesday, April 27, 2010 General News
Advertisement
NEW YORK, April 26 Reportlinker.com announces that a new market research report is available in its catalogue:

The Worldwide Market for Cancer Diagnostics, 4th Edition
Advertisement

http://www.reportlinker.com/p0187227/The-Worldwide-Market-for-Cancer-Diagnostics-4th-Edition.html

"Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound. Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And new entrants have entered the field.
Advertisement

These changes and more are addressed in Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:



Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease.

Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:



This report includes market analysis of the following screening tests: The Cancer Profile, CTC, Fecal Occult Blood, PSA, H. pylori, IHC, ISH

As well as tests for specific cancers:



This latest edition of Kalorama Information's study takes a fresh look at all of these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:

This allows the reader to match his or her own situation to the market at large.

In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles.

Top Tier Companies



Status Quo Leader Companies









New Entrants





















The various diagnostic techniques and trends are discussed from the point of view of their present and potential market impact. Therefore, the report does not provide an in depth discussion of the etiology, physiology and clinical manifestations of cancer except where an understanding of these areas is required to understand the impact that new and early diagnostics exert on patient care. Similarly, the report does not describe the technical aspects of the test modalities, for example

All market data is based on factory sales to the end user and not retail pricing or reimbursement payments. For cancer testing, this means that the actual dollar market - that is what manufacturers earn from the sale of their products is undervalued. This is because many of the new tests are offered as test services either by the companies that have developed the tests and/or their partners.

Market data is presented in dollar market size for categories of tests, and for specific analytes where possible. Here the dollar value of a market segment is directly proportional to the number of tests performed, because the cost of the instrumentation is generally buried in the per test price.

The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally, current products and technologies establish the standard of care and its value to payers. Many of the assays and imaging techniques presented in the report are expected to replace the standard of care in 2010, but with healthcare systems' emphasis on cost/benefit analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.

The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics, imaging industries and cancer specialists."

CHAPTER ONE: Executive Summary

Introduction

Scope and Methodology

Size and Growth of the Market

Test Segments

Geographic Distribution

Market Trends

Death Rates

Revolutionary Therapeutics

Physician Factor

Consumer Lobby

Price

CHAPTER TWO: Introduction

Background

Pharmacogenomics

Test Service Commercialization

Cancer - Diagnosis and Therapy Management

Point of View

CHAPTER THREE: Market Trends In The Commercialization Of Cancer Diagnostics

Background

Demographics of Cancer, a Global Phenomenon

Cancer Testing in the World:

Screening and Government Supported Programs

United States of America

International

Europe

Mexico

China

India

Reimbursement and Commercialization of Novel Tests

Test Services - Route for Cancer Innovation

Table 3-3

Regulatory requirements of new products

Strategic Alliances and Partnerships

Personalized Medicine Advances

Gene Patents and Test Commercialization

CHAPTER FOUR: Technological Trends

Background

Biomarker Revolution

The promise of Personalized Medicine

Miniaturization and Multiplexed Biological Assays

The emergence of non-invasive tools

New Technologies Applied To Cancer Diagnostics

Overview

New Platforms

Mass Spectrometry

Chromosome Analysis

Next-Generation Sequencing

RNA - Ribonucleic Acid

The In Vitro/In Vivo Mix

CHAPTER FIVE: Market Analysis

Background

World Regional Segments of the Market for Cancer Diagnostics

Companies and Products

Has Screening Lost its Allure?

Cancer Specific Tests

Bladder Cancer

Breast Cancer

Cervical Cancer

Colon Cancer

Lung Cancer

Ovarian Cancer

Prostate Cancer

CHAPTER SIX: Cancer Tests in IVD Segments (Segment Analysis)

Cancer Diagnostics and IVD Markets

The Market For Cancer Tests In Clinical Chemistry

The Market For Immunoassay Cancer Tests, Lab & Rapid

Point-of-care

The Market for Cancer Tests in Histology / Cytology

Traditional Tissue Stains

Pap Smear and HPV Testing

IHC/ISH

The Market for Tissue Microarrays

The Market For Cancer Tests in Flow Cytometry

The Market for Circulating Tumor Cells in Cancer Diagnostics

The Market For Cancer Molecular Assays

The Market For Cancer Tests in Pharmacodiagnostics

The market for Biochips and Arrays in Cancer Diagnostics

The Commercial Outlook for Cancer Diagnostics

CHAPTER SEVEN: Conclusions

Conclusions and Strategic Implications

Conclusion 1

Implication:

Conclusion 2

Implication:

Conclusion 4

Implication

Conclusion 5

Implication:

Conclusion 6:

Unmet Market Needs

Unmet Need #1

Unmet Need #2

Unmet Need #3

CHAPTER EIGHT: The Top Tier of IVD Companies and their investment in cancer diagnostics

Abbott Diagnostics

Molecular Histology

Molecular Diagnostics

Immunoassays

Beckman Coulter Inc

FOB

Flow Cytometry

Becton, Dickinson and Company (BD)

Histology

bioMerieux Inc

Bio-Rad Laboratories Inc

Dako A/S

Fujirebio Diagnostics, Inc

Gen-Probe Inc

Hologic, Inc

Histology

HPV

Inverness Medical Innovations

Ortho Clinical Diagnostics

QIAGEN N.V

Roche Diagnostics Indianapolis, IN www.roche.com Recent Revenue History ($ million)

Histology

Immunoassays

PCR

Research

Siemens Medical Solutions Diagnostics

Molecular

In Vivo

Sysmex Corporation

CHAPTER NINE: The Status Quo in Cancer Diagnostics

AdnaGen AG

Agendia BV

AMDL Diagnostics, Inc. (ADI)

American Diagnostica Inc

Aperio Technologies, Inc

Asuragen, Inc

AviaraDx

Binding Site (The) Ltd

BioCurex Inc

BioGenex Laboratories, Inc

BioImagene

Bio-Reference Laboratories, Inc

Biotage AB

bioTheranostics

BioView Ltd

Celera Diagnostics

China Medical Technologies, Inc

Cisbio Bioassays

Clarient Inc. (formerly ChromaVision)

Clinical Data, Inc

CytoCore, Inc

DxS Ltd

Epigenomics AG

Genetix Applied Imaging

Genomic Health, Inc

Genzyme Genetics

Health Discovery Corporation

HistoRx, Inc

Ikonisys, Inc

InterGenetics Inc

Ipsogen SA

Lab21 Healthcare

Laboratory Corporation of America Holdings (LabCorp)

Life Technologies

Monogram Biosciences, Inc

mtm laboratories AG

Myriad Genetics, Inc

Nanosphere, Inc

OncoVista Innovative Therapies, Inc

Pathwork Diagnostics

Precision Therapeutics

Prometheus Laboratories Inc

Quest Diagnostics

Response Genetics, Inc

Rosetta Genomics Ltd

Sequenom

Transgenomic Inc

Veridex, LLC

Vermillion Inc

Zila, Inc

CHAPTER TEN: New Entrants And Novel Product Developers

20/20 GeneSystems, Inc

454 Life Sciences Corporation

Acrometrix Corporation (Life Tech.)

Acupath Laboratories, Inc

Advalytix

Affymetrix, Inc

Allegro Diagnostics

Althea Technologies, Inc

Amorfix Life Sciences Ltd

Arbor Vita Corporation

ArcticDx Inc

Arrayit Diagnostics Inc

AVEO Pharmaceuticals, Inc

Axela, Inc

Baypoint Biosystems, Inc

Biodesix, Inc

Biologix Diagnostics, LLC

BioMarker Strategies, LLC

Biomoda

BioMosaics

BioProspecting NB, Inc. (BPNBI)

BioServe

Biosystems International SAS (BSI)

BioTrove, Inc

Cambridge Research & Instrumentation, Inc. (CRi)

Cangen Biotechnologies, Inc

Caris Diagnostics

Castle Biosciences Inc

Celerus Diagnostics

Cell Biosciences

CeMines, Inc

Cepheid

ChromoCure Inc

Chronix Biomedical Inc

Clinical Genomics Pty Ltd

CombiMatrix Molecular Diagnostics (CMDX)

Comprehensive Cancer Cell (CCC) Diagnostics Inc

Compugen Ltd

Correlogic Systems, Inc

CS-Keys, Inc

deCode Genetics Inc. ---

DiaGenic ASA

DiagnoCure --

Diagnoplex

Diagnostic Biosystems Company

DNA Direct, Inc

DexTerity Diagnostics

EDP Biotech Corporation

Epistem Plc

Exact Sciences Corp

Exiqon A/S

ExonHit Therapeutics

Exosome Diagnostics Inc

Expression Pathology Inc

Falcon Genomics, Inc

FASgen Diagnostics, LLC

Fluxion Biosciences

Foligo Therapeutics, Inc

Gastrocor

Genelex Corporation

GeneNews Limited

Genoptix

iKaryos Diagnostics

Illumina

Inostics GmbH

InteRNA Technologies B.V

Intrinsic Bioprobes Inc

Invirion Diagnostics, LLC

InVivoScribe Technologies

Iris BioTechnologies Inc

IRIS International, Inc

MabCure Inc

MacroArray Technologies, LLC

MagArray Inc

Martell Biosystems, Inc

Med BioGene, Inc. (MBI)

Medical Prognosis Institute

Metabolon, Inc

Miraculins Inc

MolecularMD Corp

Neogenix Oncology, Inc

NextGen Sciences

Nuvera Biosciences

Olink AB

Oncimmune LLC

OncoMethylome Sciences S.A

On-Q-ity

Orion Genomics

Oxford BioTherapeutics

Pacific Edge Biotechnology Ltd. (PEB)

Photocure ASA

Power3 Medical Products, Inc

Prediction Sciences

Predictive Biosciences

PrognosDx Health, Inc

Provista Life Sciences LLC

Rubicon Genomics, Inc

Rules-Based Medicine, Inc. (RBM)

Saladax Biomedical, Inc. (SBI)

SensiGen LLC

Sienna Cancer Diagnostics

Signature Genomic Laboratories, LLC

Singulex Inc

Skyline Diagnostics B.V

Source MDx

Soar BioDynamics, Ltd

Strategic Diagnostics Inc

Synergenz Bioscience Ltd

Targeted Molecular Diagnostics (TMD)

Theranostics Health (TH)

TrimGen Corporation

TrovaGene, Inc

Vitatex Inc

WaferGen Biosystems, Inc

Xceed Molecular (formerly MetriGenix Corporation)

Zetiq Technologies Ltd

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER THREE: MARKET TRENDS

Table 3-1: Participation rates of CRC screening in National Programs and Pilot Studies

Table 3-2: Selected Lab Service Cancer Tests Launched in 2008 & 2009

Table 3-4: Selected acquisitions and mergers, 2008-2009

Table 3-5: Selected Company Alignments for Cancer Diagnostics, 2008-2009

Table 3-6: Selected collaborations Between IVD and Pharmaceutical Companies, 2008-2009

Table 3-7: U.S. Patents for Selected Molecular Test Platforms

CHAPTER FOUR: TECHNOLOGY TRENDS

Table 4-1: Selected Novel Biomarkers Under Investigation

Table 4-2: Selected biochip test and service innovations, 2008-2009

Table 4-3: Selected Innovations in Blood-Based Cancer Diagnostics, 2008-2009

Table 4-4: Selected non-invasive cancer test innovations, 2008-2009

Table 4-5: Selected test platform innovations, 2008-2009

Table 4-6: Selected companies involved in chromosomal analysis of cancer cells

CHAPTER FIVE: MARKET ANALYSIS

Table 5-1: World Cancer Statistics, new cases per year

Table 5-2: World Population, Cancer Patients and Percentage of Cancer Market IVD Statistics, 2005

Table 5-3: World Cancer Test Sales, by Region, 2009-2014

Table 5-4: Revenues of Selected Cancer Testing Companies($MM)

Table 5-5: Selected Underperformers in the Cancer Market, 2008-2009

Table 5-6: Cancer Diagnostics and the Top Tier of IVD Companies

Table 5-7: Selected new histological breast cancer tests, 2008-2009

Table 5-8: Selected Breast Cancer Test Innovations, 2008-2009

Table 5-9: Selected HPV test innovations, 2008-2009

Table 5-10: Selected colon cancer test innovations, 2008-2009

Table 5-11: Selected PGx tests for colon cancer, 2008-2009

Table 5-12: Selected Lung Cancer Innovations, 2008-2009

Table 5-13: Selected Ovarian Cancer Test Innovations, 2008-2009

Table 5-14: Selected Prostate Cancer Test Innovations, 2008-2009

CHAPTER SIX: SEGMENT MARKET ANALYSIS

Table 6-1: Worldwide Market for Selected Cancer In Vitro Diagnostics (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, CTCs, Pharmacodiagnostics) 2009-2014

Table 6-2: Selected Tissue Function Clinical Chemistry Tests

Table 6-3: Major Players For Clinical Chemistry Analyzers And Reagents

Table 6-4: Selected Innovations in Cancer Immunoassays, 2008-2009

Table 6-5: Cancer Immunoassay Sales, Lab-based, (PSA, CEA, CA 125, AFP, Others), 2009-2014

Table 6-6: Rapid Cancer Test Sales by Test Category (Fecal Occult Blood, PSA H Pylori, NMP22, Other), Worldwide 2009-2014

Table 6-7: Worldwide Histology/Cytology Sales (Traditional Non Pap, Pap, IHC, ISH, Image Cytometry, Tissue Micorarrays) 2009-2014

Table 6-8: Selected Vendors of Traditional Histology Stains

Table 6-9: Selected HPV Tests Innovations, 2008-2009

Table 6-10: Major Protein and Molecular Markers Used in Tissue Staining

Table 6-11: Selected Chromosome-Based Cancer Tests, 2008-2009

Table 6-12: Selected Digital Imaging Innovations, 2008-2009

Table 6-13: Selected Histopathology Innovations, 2008-2009

Table 6-14: Selected Tissue Microarray Products, 2008-2009

Table 6-15: Selected molecular Cancer Test Innovations, 2008-2009

Table 6-16: Selected Cancer PGx Test Innovations, 2008-2009

Table 6-17: Selected Array-Based Cancer Test Innovations, 2008-2009

Table 6-18: Technology Penetration Forecast for Cancer IVDs 2005-2025 (Minor Role, Moderate Role, Major Role, Rarely Used)

To order this report:

Diagnostics Industry: The Worldwide Market for Cancer Diagnostics, 4th Edition

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

-- Histology/Cytology

SOURCE Reportlinker
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close